Answers are grounded in this paper and cite their sources.
The number of doses of vaccine against coronavirus disease (COVID-19) is limited in most countries but some doses are administrated to already immunized asymptomatic people. With serological triages, we could reach an effective collective immunization 1 swifter and potentially reduce allergic/ immunological reactions (anaphylaxis 2 ), blood clots, or other uncommon disorders following vaccine(s). Triages should concern all people; anti-spike antibodies could be ignored after asymptomatic COVID-19 but could also be missing after symptomatic COVID-19 (T-cell immunity). For immunized people (post-infection or/and post-vaccination), persistent immunity could be assessed each 8 months 4 or more, according to risk(s) of severe COVID-19 and death. xceptions could be made, as a vaccine(s) could treat long COVID-19 cases in which anti-Spike antibodies seem insufficient but this hypothesis should be confirmed.
No takes yet. Share an insight, caveat, or question.
Blavier et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: